In HIV–HBV-coinfected patients from sub-Saharan Africa, incidence of antiviral resistant HBV-mutations after initiating long-term antiretroviral therapy (ART) has only been evaluated in limited patient populations.
Methods
In this nested, prospective cohort study from two randomized controlled trials in Côte d'Ivoire, 168 ART-naive HIV–HBV-coinfected patients, starting lamivudine (LAM, n=82) or tenofovir/emtricitabine (TDF/FTC, n=86) containing ART were included. HBV DNA viral load (VL) was quantified using an in-house assay (detection limit: <12 copies/ml) while pol and preS/S regions of positive samples were sequenced.
Results
At ART-initiation, 39 (23.2%) were hepatitis B e antigen-positive, 53 (31.5%) had alanine or aspartate aminotransferase levels >40 IU/ml and 98/100 (98.0%) harboured genotype E. Among the 127 (75.6%) patients with detectable baseline HBV VL (median 4.27 log10 copies/ml, IQR 3.14–7.64), cumulative percentage achieving undetectable HBV DNA was 74.2% for patients undergoing LAM-containing ART and 94.2% for TDF/FTC-containing ART after a median 35.5 months (IQR 24.3-36.5). No baseline antiviral resistance mutations were observed. Among 28/127 (22.1%) patients with low-level persistent viraemia (last HBV VL: between 12 to <105 copies/ml), no incident amino acid changes associated with antiviral resistance were observed. Among 11/127 (8.7%) patients with high-level persistent viraemia (last HBV VL: ≥105 copies/ml), only two harboured incident LAM-resistance mutations at positions rtV173L+rtL180M+rtM204V with no patient exhibiting TDF/FTC-resistance. Two patients had transaminase fares >120 IU/ml (incidence rate =0.5/100 person-years).
Conclusions
Antiviral resistance, particularly to LAM, was remarkably rare in this cohort of HIV-HBV-coinfected patients. Further research is needed to determine which coinfected populations might benefit from LAM-containing ART with low risk of resistance.
References
1.
Data Collection on Adverse Events of Anti-HIV drugs D:A:D Study Group, Smith C, Sabin CA, et al.Factors associated with specific causes of death amongst HIV-positive individuals in the D:A: Study D.AIDS2010; 24: 1537–1548.
2.
JoshiD., O'GradyJ., DieterichD., GazzardB., AgarwalK.Increasing burden of liver disease in patients with HIV infection.Lancet2011; 377: 1198–1209.
3.
Salmon-CeronD., RosenthalE., LewdenC.Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study.J Hepatol2009; 50: 736–745.
4.
Falade-NwuliaO., SeabergE.C., RinaldoC.R., BadriS., WittM., ThioC.L.Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection.Clin Infect Dis2012; 55: 507–513.
5.
ChenC-F, LeeW-C, YangH-I, ChangH-C, JenC-L, IloejeU.H.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.Gastroenterol2011141: 1240–1248.
6.
GishR., JiaJ-D, LocarniniS., ZoulimF.Selection of chronic hepatitis B therapy with high barrier to resistance.Lancet Infect Dis2012; 12: 341–353.
7.
MatthewsG.V., BartholomeuszA., LocarniniS.Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.AIDS2006; 20: 863–870.
8.
HamersR.L., ZaaijerH.L., WallisC.L.HIV-HBV coinfection in southern Africa and the effect of lamivudine-versus tenofovir-containing cART on HBV outcomes.J Acquir Immune Defic Syndr2013; 64: 174–182.
9.
KouanfackC., AghokengA.F., MondainA-MLamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.Antivir Ther2012; 17: 321–326.
10.
SelabeS.G., LukhwareniA., SongE., LeeuwY.G.M., BurnettR.J., MphahleleM.J.Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.J Med Virol2007; 79: 1650–1654.
11.
ChadwickD., AnkcornM., SarfoF.Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/ HIV-coinfected patients in Ghana.J Antimicrob Chemother2012; 67: 2939–2942.
12.
KimH.N., ScottJ., CentA.HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.J Viral Hepat2011; 18: e447–e452.
13.
StewartB., JobartehM.L., Sarge-NjieR.Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.BMC Res Notes2011; 4: 561.
14.
DayS.L., Odem-DavisK., MandaliyaK.N.Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy.PLoS ONE2013; 8: e59346.
15.
TorresiJ.The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.J Clin Virol2002; 25: 97–106.
16.
KamiliS., SozziV., ThompsonG.Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.Hepatology2009; 49: 1483–1491.
17.
LocarniniS.A., YuenL.Molecular genesis of drug-resistant and vaccine-escape HBV mutants.Antivir Ther2010; 15: 451–461.
18.
LacombeK., BoydA., LavocatF.High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.Hepatology2013; 58: 912–922.
19.
DanelC., MohR., MingaA.CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.Lancet2006; 367: 1981–1989.
20.
JeanK., GabillardD., MohR.Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire.J Infect Dis2014; 209: 431–440.
21.
RouetF., EkoueviD.K., ChaixM-LTransfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.J Clin Microbiol2005; 43: 2709–2717.
22.
BoydA., GozlanJ., MaylinS.Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.Hepatology2014; 60: 497–507.
23.
JungB.H., RezkN.L., BridgesA.S., CorbettA.H., KashubaA.D.M.Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.Biomed Chromatogr2007; 21: 1095–1104.
24.
KramvisA., KewM.C.Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes.Hepatol Res2007; 37Suppl 1: S9–S19.
25.
Ganne-CarriéN., WilliamsV., KaddouriH.Significance of hepatitis B virus genotypes A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis District of Paris (France).J Med Virol2006; 78: 335–340.
26.
ErhardtA., GöbelT., LudwigA.Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.J Med Virol2009; 81: 1716–1720.
27.
BoglioneL., CardellinoC.S., De NicolòA., CaritiG., Di PerriG., D'AvolioA.Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.J Med Virol2014; 86: 1845–1850.
28.
RamosB., NúñezM., Martín-CarboneroL.Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.J Acquir Immune Defic Syndr2007; 44: 557–561.
29.
BenhamouY., BochetM., ThibaultV.Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.Hepatology1999; 30: 1302–1306.
30.
HadziyannisS.J.Natural history of chronic hepatitis B in Euro-Mediterranean and African countries.J Hepatol2011; 55: 183–191.
31.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues.Gastroenterol2009137: 1593–1608.
32.
ChildsK., JoshiD., ByrneR.Tenofovir based combination therapy for HIV/HBV co-infection: Factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.AIDS2013; 27: 1443–1448.
33.
ThioC.L., SmeatonL., SaulynasM.Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.AIDS2013; 27: 191–201.
34.
MatthewsG.V., ManziniP., HuZ.Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/ hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.AIDS2011; 25: 1727–1735.
35.
PalA., SarkarN., SahaD.High incidence of lamivudine-resistance associated vaccine-escape HBV mutant among HIV-coinfected patients on prolonged antiretroviral therapy.Antivir Ther2015; doi:10.3851/IMP2942.
36.
IroezinduM.O., DaniyamC.A., AgbajiO.O., IsaE.S., OkekeE.N., ImadeG.E.Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria.J Infect Dev Ctries2013; 7: 951–959.
37.
AoudjaneS., ChapondaM., González Del CastilloA.A.Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.Clin Infect Dis2014; 59: 1618–1626.
38.
ZoulimF., LocarniniS.Management of treatment failure in chronic hepatitis B.J Hepatol2012; 56Suppl 1: S112–S122.
39.
LacombeK., BotteroJ., LemoineM., BoydA., GirardP.M.HIV/hepatitis B virus co-infection: current challenges and new strategies.J Antimicrob Chemother2010; 65: 10–17.
40.
HoffmannC.J., ThioC.L.Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.Lancet Infect Dis2007; 7: 402–409.
41.
BurnettR.J., LarsonH.J., MoloiM.H.Addressing public questioning and concerns about vaccination in South Africa: a guide for healthcare workers.Vaccine2012; 30Suppl 3: C72–C78.
42.
MatthewsG.V., AvihingsanonA., LewinS.R.A randomized trial of combination hepatitis B therapy in HIV/ HBV coinfected antiretroviral naive individuals in Thailand.Hepatology2008; 48: 1062–1069.
43.
IserD.M., AvihingsanonA., WisedopasN.Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression.AIDS2011; 25: 197–205.
44.
MartinN.K., DevineA., EatonJ.W.Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.AIDS2014; 28Suppl 1: S35–S46.
45.
DoreG.J., SorianoV., RockstrohJ.Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.AIDS2010; 24: 857–865.
46.
MatthewsG.V., SeabergE.C., AvihingsanonA.Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.Clin Infect Dis2013; 56: e87–e94.
47.
HoffmannC.J., CharalambousS., MartinD.J.Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.Clin Infect Dis2008; 47: 1479–1485.
48.
HawkinsC., ChristianB., YeJ.Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania.AIDS2013; 27: 919–927.
49.
KimH.N., RodriguezC.V., Van RompaeyS.Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV–HIV in the CNICS Cohort.J Acquir Immune Defic Syndr2014; 66: 96–101.
50.
AmicoK.R., MarcusJ.L., McMahanV.Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.J Acquir Immune Defic Syndr2014; 66: 530–537.
